Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

28.6%

8 terminated/withdrawn out of 28 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

58%

7 of 12 completed trials have results

Key Signals

7 with results6 terminated

Enrollment Performance

Analytics

Phase 2
11(42.3%)
Early Phase 1
6(23.1%)
Phase 1
6(23.1%)
N/A
3(11.5%)
26Total
Phase 2(11)
Early Phase 1(6)
Phase 1(6)
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (28)

Showing 20 of 28 trials
NCT02905591Phase 2Active Not Recruiting

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

Role: collaborator

NCT02344355Phase 2Active Not Recruiting

A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme

Role: collaborator

NCT04900792Phase 1Active Not Recruiting

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

Role: collaborator

NCT06148636Early Phase 1Active Not Recruiting

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

Role: collaborator

NCT01852890Phase 1Completed

Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I

Role: collaborator

NCT02905578Phase 2Completed

A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)

Role: collaborator

NCT03335670Early Phase 1Active Not Recruiting

Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors

Role: collaborator

NCT05111509Early Phase 1Active Not Recruiting

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Role: collaborator

NCT05557708Early Phase 1Not Yet Recruiting

A Safety Study of 212Pb-Pentixather Radioligand Therapy

Role: collaborator

NCT07026214Not ApplicableCompleted

Feasibility, Acceptability, and Preliminary Efficacy of a Remotely-delivered Health Coaching Intervention for Cancer Survivors

Role: collaborator

NCT03541486Phase 2Withdrawn

A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients

Role: collaborator

NCT03658343Completed

T2* MRI Analysis for Sarcoma

Role: collaborator

NCT02420314Phase 2Completed

Pharmacological Ascorbate for Lung Cancer

Role: collaborator

NCT03389451Phase 2Completed

68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer

Role: collaborator

NCT03388346Phase 2Completed

68Ga PSMA in Preprostatectomy Patients

Role: collaborator

NCT03724409Early Phase 1Terminated

Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases

Role: collaborator

NCT03044977Early Phase 1Active Not Recruiting

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

Role: collaborator

NCT02959164Phase 1Completed

Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma

Role: collaborator

NCT03688347Completed

Microbiome in Lung Cancer and Other Malignancies

Role: collaborator

NCT03506139Phase 2Withdrawn

Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma

Role: collaborator